These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25016628)

  • 1. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia.
    Small S
    Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628
    [No Abstract]   [Full Text] [Related]  

  • 2. Obinutuzumab breaks through to FDA approval.
    Cancer Discov; 2014 Jan; 4(1):OF6. PubMed ID: 24402958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
    [No Abstract]   [Full Text] [Related]  

  • 4. Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy.
    Traynor K
    Am J Health Syst Pharm; 2013 Dec; 70(24):2162. PubMed ID: 24296835
    [No Abstract]   [Full Text] [Related]  

  • 5. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
    Kakkar AK; Balakrishnan S
    J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Berlex Laboratories to market new treatment for B-CLL.
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):3. PubMed ID: 12113127
    [No Abstract]   [Full Text] [Related]  

  • 7. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
    Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obinutuzumab in chronic lymphocytic leukemia.
    Dupuis J
    Future Oncol; 2015 Sep; 11(18):2503-13. PubMed ID: 26285615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab looks impressive in CLL.
    Cancer Discov; 2014 Apr; 4(4):OF5. PubMed ID: 24706674
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Demko S; Summers J; Keegan P; Pazdur R
    Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.
    Ysebaert L; Laprévotte E; Klein C; Quillet-Mary A
    Blood Cancer J; 2015 Nov; 5(11):e367. PubMed ID: 26565404
    [No Abstract]   [Full Text] [Related]  

  • 12. Next-generation cancer biologics shine in studies.
    Dalzell MD
    Manag Care; 2013 Oct; 22(10):58-9. PubMed ID: 24350384
    [No Abstract]   [Full Text] [Related]  

  • 13. Ofatumumab.
    Keating MJ; Dritselis A; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Feb; 9(2):101-2. PubMed ID: 20118960
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention and management of obinutuzumab-associated toxicities: Australian experience.
    Snowden A; Hayden I; Dixon J; Gregory G
    Int J Nurs Pract; 2015 Dec; 21 Suppl 3():15-27. PubMed ID: 26681665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ofatumumab approved for advanced CLL.
    Traynor K
    Am J Health Syst Pharm; 2009 Dec; 66(23):2062. PubMed ID: 19923303
    [No Abstract]   [Full Text] [Related]  

  • 16. Acalabrutinib: First Global Approval.
    Markham A; Dhillon S
    Drugs; 2018 Jan; 78(1):139-145. PubMed ID: 29209955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treanda approved for chronic lymphocytic leukemia.
    Traynor K
    Am J Health Syst Pharm; 2008 May; 65(9):793. PubMed ID: 18436722
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of obinutuzumab in chronic lymphocytic leukemia.
    Wierda W
    Clin Adv Hematol Oncol; 2014 Jun; 12(6):395-7. PubMed ID: 25003571
    [No Abstract]   [Full Text] [Related]  

  • 19. Obinutuzumab: the more the merrier?
    Burger JA
    Blood; 2016 Jan; 127(1):6-8. PubMed ID: 26744434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.